Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
17
LUNG Quote, Financials, Valuation and Earnings
Last price:
$1.33
Seasonality move
:
-24.38%
Day range:
$1.24 - $1.34
52-week range:
$1.13 - $7.03
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.62x
P/B ratio:
1.08x
Volume:
177.6K
Avg. volume:
671.3K
1-year change:
-80.5%
Market cap:
$58.4M
Revenue:
$90.5M
EPS (TTM):
-$1.33
Analysts' Opinion
-
Consensus RatingPulmonx Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.17, Pulmonx Corp. has an estimated upside of 288.47% from its current price of $1.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $1.33.
Fair Value
-
According to the consensus of 5 analysts, Pulmonx Corp. has 288.47% upside to fair value with a price target of $5.17 per share.
LUNG vs. S&P 500
-
Over the past 5 trading days, Pulmonx Corp. has overperformed the S&P 500 by 3.77% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pulmonx Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pulmonx Corp. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pulmonx Corp. reported revenues of $22.6M.
Earnings Growth
-
Pulmonx Corp. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Pulmonx Corp. reported earnings per share of -$0.25.
Enterprise value:
42.5M
EV / Invested capital:
--
Price / LTM sales:
0.62x
EV / EBIT:
--
EV / Revenue:
0.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$66.9M
Return On Assets:
-36.59%
Net Income Margin (TTM):
-59.67%
Return On Equity:
-77.88%
Return On Invested Capital:
-42.87%
Operating Margin:
-43.82%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $68.7M | $83.8M | $90.5M | $23.8M | $22.6M | |
| Gross Profit | $50.7M | $61.9M | $66.9M | $17.6M | $17.5M | |
| Operating Income | -$61.9M | -$56M | -$53.7M | -$13.4M | -$9.9M | |
| EBITDA | -$59M | -$54.4M | -$52.4M | -$13.1M | -$9.7M | |
| Diluted EPS | -$1.60 | -$1.44 | -$1.33 | -$0.33 | -$0.25 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $208M | $169M | $150.3M | $136.2M | $101.5M | |
| Total Assets | $235.7M | $194.1M | $179M | $167.7M | $134M | |
| Current Liabilities | $17.6M | $18.5M | $23.2M | $24.4M | $20.1M | |
| Total Liabilities | $42.4M | $40.1M | $60.6M | $81.9M | $79.8M | |
| Total Equity | $193.2M | $154M | $118.3M | $85.8M | $54.1M | |
| Total Debt | $24.3M | $21.1M | $38.4M | $55.7M | $55.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.6M | -$31.5M | -$32.4M | -$6.7M | -$7.1M | |
| Cash From Investing | -$2M | $17.5M | $30.5M | $14.1M | -$13K | |
| Cash From Financing | $21.4M | $1.4M | $903K | $62K | $55K | |
| Free Cash Flow | -$38.4M | -$33M | -$32.9M | -$6.8M | -$7.1M | |
LUNG
Sector
Market Cap
$58.4M
$23.9M
Price % of 52-Week High
18.93%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-1.21%
-1.9%
1-Year Price Total Return
-80.5%
-18.29%
Beta (5-Year)
0.187
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.26
200-day SMA
Sell
Level
$1.91
Bollinger Bands (100)
Sell
Level
1.4 - 2.14
Chaikin Money Flow
Sell
Level
-2.4M
20-day SMA
Sell
Level
$1.49
Relative Strength Index (RSI14)
Sell
Level
42.78
ADX Line
Sell
Level
46.8
Williams %R
Neutral
Level
-66.3866
50-day SMA
Sell
Level
$1.54
MACD (12, 26)
Buy
Level
0.33
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-2.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.6759)
Sell
CA Score
(Annual)
Level (-1.9997)
Buy
Beneish M-Score
(Annual)
Level (-3.108)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.2669)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, LUNG has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LUNG average analyst price target in the past 3 months is $5.17.
-
Where Will Pulmonx Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pulmonx Corp. share price will rise to $5.17 per share over the next 12 months.
-
What Do Analysts Say About Pulmonx Corp.?
Analysts are divided on their view about Pulmonx Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pulmonx Corp. is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Pulmonx Corp.'s Price Target?
The price target for Pulmonx Corp. over the next 1-year time period is forecast to be $5.17 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is LUNG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pulmonx Corp. is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LUNG?
You can purchase shares of Pulmonx Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pulmonx Corp. shares.
-
What Is The Pulmonx Corp. Share Price Today?
Pulmonx Corp. was last trading at $1.33 per share. This represents the most recent stock quote for Pulmonx Corp.. Yesterday, Pulmonx Corp. closed at $1.33 per share.
-
How To Buy Pulmonx Corp. Stock Online?
In order to purchase Pulmonx Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LUNG Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LUNG
Sector
P/E ratio
--
21.37x
PEG ratio
--
-0.01x
P/B ratio
1.08x
1.72x
Price / LTM sales
0.62x
1.44x
Growth Metrics
LUNG
Sector
Revenue growth
-4.91%
3.44%
Earnings growth
24.36%
14.97%
Revenue (5-year growth)
22.56%
6.27%
Earnings forecast
-$0.33
-$0.22
Profitability
LUNG
Sector
Profitability FY 2025
$67M
$2.4M
Return on invested capital
-42.87%
-33.43%
Return on assets
-36.59%
-29.45%
Return on equity
-77.88%
-40.29%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Apr
29
Estimated Next Earnings Date
Feb
11
Balance Sheet
LUNG
Sector
Total cash
$70M
$25.6M
Short term investments
$30.6M
$22.7M
Total assets
$134M
$70.4M
Long term debt
$55.2M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
